Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.61 |
| ▸ | CDC25C | P30307 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239269 | 0.89 | KCNH2 (0.63) | KCNH2CDC25CMEN1KMT2ATHRB | |
| SCHEMBL26239268 | 0.86 | KCNH2 (0.54) | KCNH2CDC25CMEN1KMT2ATHRB | |
| SCHEMBL26239281 | 0.82 | KCNH2 (0.49) | KCNH2CDC25CMEN1KMT2ATHRB | |
| SCHEMBL5109206 | 0.81 | L3MBTL1 (0.53) | KCNH2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL24600583 | 0.80 | KCNH2 (0.46) | KCNH2BLMSIGMAR1ALDH1A1MAPT | |
| SCHEMBL10721556 | 0.80 | KCNH2 (0.62) | KCNH2CDC25CMEN1KMT2ATHRB | |
| SCHEMBL9097438 | 0.79 | MEN1 (0.50) | MEN1KMT2ATDP1ALDH1A1MAPT | |
| SCHEMBL733055 | 0.79 | CYP19A1 (0.53) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28060807 | 0.78 | ALDH1A1 (0.51) | MEN1KMT2ATDP1ALDH1A1MAPT | |
| SCHEMBL26239254 | 0.78 | ALDH1A1 (0.48) | MEN1KMT2ATDP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACAD PHARMACEUTICALS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INC (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885CDC25C 3526/4885MEN1 4508/4885 |
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885CDC25C 3526/4885MEN1 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.